In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dendreon vs. CMS: "Full Coverage" or the CED Solution?

This article was originally published in RPM Report

Executive Summary

A Medicare advisory committee brought few surprises for Dendreon’s prostate cancer therapy Provenge. Will CMS provide full coverage for Provenge or will it restrict use through coverage with evidence development?
Advertisement

Related Content

FDA-CMS Parallel Review Pilot Will Be Extended; Drugs Not The Focus
Upheaval And Opportunity Reshape The Oncology Market
Teenage Wasteland: Paying for New Drugs and Other "Adolescent" Technologies
Straight Talk About Cancer Drug Coverage
Straight Talk About Cancer Drug Coverage
Dendreon vs. CMS:Controversy Is Bigger Than One Product
Dendreon vs. CMS:Controversy Is Bigger Than One Product
Dendreon and InterMune: Do They Mean Anything for the Regulatory Climate at FDA?
Coverage with Evidence Development: A Road to Accelerated Biomarker Adoption

Topics

Advertisement
UsernamePublicRestriction

Register

PS080755

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel